

The Biology Behind

- Idiotypic Vaccination Strategies in Myeloma: How to Overcome a Dysfunctional Immune System.**
□□ *Commentary on Hansson et al., p. 1503*
Frits van Rhee1353

Molecular Pathways

- Cancer Cachexia Signaling Pathways Continue to Emerge Yet Much Still Points to the Proteasome.** Swarnali Acharyya and Denis C. Guttridge1356

- Regulation of Metastases by Signal Transducer and Activator of Transcription 3 Signaling Pathway: Clinical Implications.** Suyun Huang1362

Report From the FDA

- Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma.**
Vicki L. Goodman, Edwin P. Rock, Ramzi Dagher, Roshni P. Ramchandani, Sophia Abraham, Jogarao V.S. Gobburu, Brian P. Booth, S. Leigh Verbois, David E. Morse, Cheng Yi Liang, Nallaperumal Chidambaram, Janet X. Jiang, Shenghui Tang, Kooros Mahjoob, Robert Justice, and Richard Pazdur1367

Reviews

- Optimization of Radioimmunotherapy of Solid Tumors: Biological Impediments and Their Modulation.**
Maneesh Jain, Ganesh Venkatraman, and Surinder K. Batra1374

- Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology.**
Kapila Ratnam and Jennifer A. Low1383

Human Cancer Biology

- Overexpression of Hedgehog Signaling Molecules and Its Involvement in the Proliferation of Endometrial Carcinoma Cells.** Yu-Zhen Feng, Tanri Shiozawa, Tsutomu Miyamoto, Hiroyasu Kashima, Miyuki Kurai, Akihisa Suzuki, Jiang Ying-Song, and Ikuo Konishi1389

- Epigenetic Silencing of the Candidate Tumor Suppressor Gene *Per1* in Non-Small Cell Lung Cancer.** Sigal Gery, Naoki Komatsu, Norihiko Kawamata, Carl W. Miller, Julian Desmond, Renu K. Virk, Alberto Marchevsky, Robert Mckenna, Hirokuni Taguchi, and H. Phillip Koeffler1399

- Amplified in Breast Cancer 1 in Human Epidermal Growth Factor Receptor-Positive Tumors of Tamoxifen-Treated Breast Cancer Patients.** Tove Kirkegaard, Liane M. McGlynn, Fiona M. Campbell, Sven Müller, Sian M. Tovey, Barbara Dunne, Kirsten V. Nielsen, Timothy G. Cooke, and John M.S. Bartlett1405

- Haplotypes, Loss of Heterozygosity, and Expression Levels of Glycine N-Methyltransferase in Prostate Cancer.** Yu-Chuen Huang, Cheng-Ming Lee, Marcelo Chen, Ming-Yi Chung, Yen-Hwa Chang, William Ji-Shian Huang, Donald Ming-Tak Ho, Chin-Chen Pan, Tony T. Wu, Stone Yang, Ming-Wei Lin, Jer-Tsong Hsieh, and Yi-Ming Arthur Chen1412

- Sperm-Associated Antigen 9, a Novel Cancer Testis Antigen, Is a Potential Target for Immunotherapy in Epithelial Ovarian Cancer.** Manoj Garg, Dipak Chaurasiya, Ritu Rana, Nirmala Jagadish, Deepika Kanojia, Namrata Dudha, Neha Kamran, Sudha Salhan, Amar Bhatnagar, Sushma Suri, Anju Gupta, and Anil Suri1421

Longitudinal Assessment of Genetic and Epigenetic Markers in Oligodendrogliomas. Iris Lavon, Daniel Zrihan, Bracha Zelikovitch, Yakov Fellig, Dana Fuchs, Dov Soffer, and Tali Siegal1429

Imaging, Diagnosis, Prognosis

Insulin-like Growth Factor Binding Proteins IGFBP3, IGFBP4, and IGFBP5 Predict Endocrine Responsiveness in Patients with Ovarian Cancer. Graeme Walker, Kenneth MacLeod, Alistair R.W. Williams, David A. Cameron, John F. Smyth, and Simon P. Langdon1438

Retropharyngeal Lymph Node Metastasis in Nasopharyngeal Carcinoma: Prognostic Value and Staging Categories. Jun Ma, Lizhi Liu, Linglong Tang, Jingfeng Zong, Aihua Lin, Taixiang Lu, Nianji Cui, Chunyan Cui, and Li Li1445

Virus-Associated Tumor Imaging by Induction of Viral Gene Expression. De-Xue Fu, Yvette C. Tanhehco, Jianmeng Chen, Catherine A. Foss, James J. Fox, Victor Lemas, Ja-Mun Chong, Richard F. Ambinder, and Martin G. Pomper1453

Translating Expression Profiling into a Clinically Feasible Test to Predict Neuroblastoma Outcome. Alexander Schramm, Jo Vandesompele, Johannes H. Schulte, Sabine Dreesmann, Lars Kaderali, Benedikt Brors, Roland Eils, Frank Speleman, and Angelika Eggert1459

Transcriptomic versus Chromosomal Prognostic Markers and Clinical Outcome in Uveal Melanoma. Lori A. Worley, Michael D. Onken, Erica Person, Diane Robirds, Julie Branson, Devron H. Char, Arie Perry, and J. William Harbour1466

High Macrophage Infiltration along the Tumor Front Correlates with Improved Survival in Colon Cancer. Johan Forssell, Åke Öberg, Maria L. Henriksson, Roger Stenling, Andreas Jung, and Richard Palmqvist1472

Downregulation of Neuroblastoma Correlates with the Differentiation Status and Aggressiveness of Neuroblastic Tumors. Darryl T. Martin, Robert L. Gendron, Jason A. Jarzembowski, Arie Perry, Margaret H. Collins, Chitra Pushpanathan, Ewa Miskiewicz, Valerie P. Castle, and Hélène Paradis1480

Cancer Therapy: Clinical

The Association Between Measures of Progression and Survival in Castrate-Metastatic Prostate Cancer. Howard I. Scher, Mary Warren, and Glenn Heller1488

Standard Treatments Induce Antigen-Specific Immune Responses in Prostate Cancer. Nancy J. Nessler, Robert A. Sahota, Brad Stone, Kayli Johnson, Navraj Chima, Caitlin King, Devon Rasmussen, Darcy Bishop, Paul S. Rennie, Martin Gleave, Paul Blood, Howard Pai, Charles Ludgate, and Brad H. Nelson1493

Long-term Idiotypic Vaccination Combined with Interleukin-12 (IL-12), or IL-12 and Granulocyte Macrophage Colony-Stimulating Factor, in Early-Stage Multiple Myeloma Patients. Lotta Hansson, Amir Osman Abdalla, Ali Moshfegh, Aniruddha Choudhury, Hodjattallah Rabbani, Bo Nilsson, Anders Osterborg, and Håkan Mellstedt1503

Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420. Alberto Broniscer, John C. Panetta, Melinda O'Shaughnessy, Charles Fraga, Feng Bai, Matthew J. Krasin, Amar Gajjar, and Clinton F. Stewart1511

A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study. Terzah M. Horton, Debananda Pati, Sharon E. Plon, Patrick A. Thompson, Lisa R. Bomgaars, Peter C. Adamson, Ashish M. Ingle, John Wright, Adam H. Brockman, Martin Paton, and Susan M. Blaney1516

Modulation of Signal Transducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFN α 2b. Wenjun Wang, Howard D. Edington, Uma N.M. Rao, Drazen M. Jukic, Stephanie R. Land, Soldano Ferrone, and John M. Kirkwood.....1523

Cancer Therapy: Preclinical

Combined Treatment with Temozolomide and Methoxyamine: Blocking Apurinic/Pyrimidinic Site Repair Coupled with Targeting Topoisomerase II α . Ling Yan, Alina Bulgar, Yanling Miao, Varun Mahajan, Jon R. Donze, Stanton L. Gerson, and Lili Liu1532

Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non-Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor. Philipp Steiner, Christopher Joynes, Rajiv Bassi, Su Wang, James R. Tonra, Yaron R. Hadari, and Daniel J. Hicklin1540

Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines. Jun Kurai, Hiroki Chikumi, Kiyoshi Hashimoto, Kosuke Yamaguchi, Akira Yamasaki, Takanori Sako, Hirokazu Touge, Haruhiko Makino, Miyako Takata, Masanori Miyata, Masaki Nakamoto, Naoto Burioka, and Eiji Shimizu1552

Inhibition of CXCR4-Mediated Breast Cancer Metastasis: A Potential Role for Heparinoids? James R. Harvey, Paul Mellor, Hesham Eldaly, Thomas W.J. Lennard, John A. Kirby, and Simi Ali1562

Mesothelin Expression in Human Lung Cancer. Mitchell Ho, Tapan K. Bera, Mark C. Willingham, Masanori Onda, Raffit Hassan, David FitzGerald, and Ira Pastan1571

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor. Tammie C. Yeh, Vivienne Marsh, Bryan A. Bernat, Josh Ballard, Heidi Colwell, Ron J. Evans, Janet Parry, Darin Smith, Barbara J. Brandhuber, Stefan Gross, Allison Marlow, Brian Hurley, Joe Lyssikatos, Patrice A. Lee, James D. Winkler, Kevin Koch, and Eli Wallace1576

NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism. David Jamieson, Kerrie Wilson, Simon Pridgeon, Jane P. Margetts, Richard J. Edmondson, Hing Y. Leung, Richard Knox, and Alan V. Boddy1584

Synergism between Etoposide and 17-AAG in Leukemia Cells: Critical Roles for Hsp90, FLT3, Topoisomerase II, Chk1, and Rad51. Qing Yao, Brenda Weigel, and John Kersey1591

Oral Lactoferrin Results in T Cell-Dependent Tumor Inhibition of Head and Neck Squamous Cell Carcinoma *In vivo*. Jeffrey S. Wolf, Guoyan Li, Atul Varadhachary, Karel Petrak, Mark Schneyer, Daqing Li, Julina Ongkasuwan, Xiaoyu Zhang, Rodney J. Taylor, Scott E. Strome, and Bert W. O'Malley, Jr.1601

Cancer Prevention


Combined Inhibitory Effects of Green Tea Polyphenols and Selective Cyclooxygenase-2 Inhibitors on the Growth of Human Prostate Cancer Cells Both *In vitro* and *In vivo*. Vaqar Mustafa Adhami, Arshi Malik, Najia Zaman, Sami Sarfaraz, Imtiaz Ahmad Siddiqui, Deebea Nadeem Syed, Farrukh Afaq, Farrukh Sierre Pasha, Mohammad Saleem, and Hasan Mukhtar1611

Letters to the Editor

- CD16^{low/negative} Tumor-Infiltrating Lymphocyte: Lymphoid or Myeloid in Origin?**
Giuseppe Sconocchia, Domenico Del Principe, and A. John Barrett.....1620
- The Complexity of Natural Killer Cells.** Elfriede Noessner and Julia S. Schleypen.....1621

About the Cover

Targeting strategies of the epidermal growth factor receptor (EGFR) with small-molecules EGFR tyrosine kinase inhibitors (TKIs) or a monoclonal antibody (cetuximab) are being developed in non-small cell lung cancer. Unlike TKIs, cetuximab potentially can provoke immunologic antitumor effects, such as antibody-dependent cellular cytotoxicity (ADCC) activity, although few studies have focused on this activity. The cover shows an immunostaining of EGFR on a cancer cell line, which express 3.51×10^6 EGFR molecules measured by quantitative flow cytometric analysis. Using these estimation methods, the authors demonstrated that even low EGFR expression levels on lung cancer cells, which are weakly detectable by immunostaining, are sufficient for maximum ADCC activity, and further increases in EGFR expression on the target cells have no further effect on the ADCC activity. For further details, please see Kurai *et al.* on page 1552 of this issue.



Clinical Cancer Research

13 (5)

Clin Cancer Res 2007;13:1353-1621.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/13/5>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/13/5>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.